A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants

Phase 1 Not yet recruiting 6 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelBasic science

Summary

This study is a single-center, open-label, single-dose phase I clinical trial. The trial is divided into four periods: screening, baseline, treatment, and follow-up

Timeline

Start: 2026-07
Primary completion: 2026-07
Completion: 2026-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-9057	Unknown	—	—

Indications

No indication recorded.